Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.
|Number of pages||4|
|Journal||Clinical infectious diseases : an official publication of the Infectious Diseases Society of America|
|Publication status||Published - 15-12-2016|
All Science Journal Classification (ASJC) codes
- Microbiology (medical)
- Infectious Diseases